Beyond Restasis: Allergan buys Oculeve dry eye device

Allergan, whose blockbuster Restasis (cyclosporine) is the only approved prescription dry eye drug in the US, is buying the device maker Oculeve for $125m to diversify the company's position in the market.

Allergan, whose blockbuster Restasis (cyclosporine) is the only approved prescription dry eye drug in the US, is buying the device maker Oculeve for $125m to diversify the company's position in the market.

There are several treatments in the clinic to treat dry eye disease, but candidates that win US FDA approval will...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip